Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
6.18
-0.57 (-8.44%)
At close: Mar 13, 2026, 4:00 PM EDT
5.99
-0.19 (-3.07%)
After-hours: Mar 13, 2026, 7:49 PM EDT
Artiva Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
152.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 251.00K | -33.24M | -99.25% |
| Dec 31, 2023 | 33.49M | 28.56M | 579.21% |
| Dec 31, 2022 | 4.93M | 2.93M | 146.30% |
| Dec 31, 2021 | 2.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 237.26M |
| Codexis | 70.39M |
| Spero Therapeutics | 40.55M |
| Equillium | 4.39M |
| Rani Therapeutics Holdings | 1.20M |
| Molecular Partners AG | 856.30K |
| Connect Biopharma Holdings | 762.00K |
| Inhibikase Therapeutics | 1.00 |
ARTV News
- 3 days ago - Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 16 days ago - Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 17 days ago - Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - GlobeNewsWire
- 22 days ago - Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - GlobeNewsWire
- 7 weeks ago - Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored - Seeking Alpha
- 4 months ago - Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease - GlobeNewsWire
- 4 months ago - Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire